| Date Filed | Type | Description |
| 06/16/2023 |
SC 13D/A
| Iroquois Capital Management, LLC reports a 5% stake in PharmaCyte Biotech, Inc. |
| 05/12/2023 |
SC 13D/A
| Iroquois Capital Management, LLC reports a 7% stake in PharmaCyte Biotech, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Iroquois Capital Management, LLC reports a 6.5% stake in MyMD Pharmaceuticals, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/15/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/28/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 07/26/2022 |
PREC14A
| Form PREC14A - Preliminary proxy statements, contested solicitations: |
| 07/15/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/11/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 07/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/05/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 06/23/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 06/23/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/23/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/23/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/23/2022 |
SC 13G/A
| Iroquois Capital Management, LLC reports a 9.6% stake in MyMD Pharmaceuticals, Inc. |
| 02/23/2022 |
SC 13G/A
| Iroquois Capital Management, LLC reports a 1.9% stake in Synthetic Biologics, Inc. |
| 02/23/2022 |
SC 13G/A
| Iroquois Capital Management, LLC reports a 3.8% stake in Oblong, Inc. |
| 02/23/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/23/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/23/2022 |
SC 13G/A
| Iroquois Capital Management, LLC reports a 5% stake in Petros Pharmaceuticals, Inc. |
| 11/04/2021 |
SC 13D
| Iroquois Capital Management, LLC reports a 5.1% stake in PharmaCyte Biotech, Inc. |
| 10/22/2021 |
SC 13G
| Iroquois Capital Management, LLC reports a 10% stake in Petros Pharmaceuticals, Inc. |
| 09/21/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/18/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/22/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/22/2021 |
SC 13G/A
| Iroquois Capital Management, LLC reports a 10% stake in AKERS BIOSCIENCES, INC. |
| 02/22/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/22/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/22/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/04/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/15/2020 |
SC 13G
| Iroquois Capital Management, LLC reports a 7.6% stake in Oblong, Inc. |
|